Sep 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

UCB reveals that BIMZELX[®] (bimekizumab-bkzx) has been approved by the U.S. FDA for treating psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.

Henlius and Intas get Positive CHMP Opinion for HETRONIFLY® (marketed as HANSIZHUANG in China) in Europe for first-line treatment in adults with extensive-stage small cell lung cancer.

Ipsen's Iqirvo® (elafibranor) receives European Union approval as the first new therapy for primary biliary cholangitis in almost ten years.

The European Commission Approves Astellas' VYLOY™ (zolbetuximab) with Chemotherapy for Advanced Stomach and Gastroesophageal Junction Cancer.

The U.S. Food and Drug Administration has greenlit Miplyffa (arimoclomol), an oral drug designed for managing Niemann-Pick disease type C (NPC).

OPUVIZ has received a recommendation for approval for adult patients in the treatment of neovascular (wet) age-related macular degeneration (AMD).

Tolebrutinib showed a 31% delay in the onset of confirmed disability progression in a phase 3 study of non-relapsing secondary progressive multiple sclerosis.

Tectonic Therapeutic Shares Positive Safety, Tolerability, and PK/PD Phase 1a Results for Lead Candidate TX45.

siRNA and ASO are two nucleic acid-based gene silencing technologies that achieve precise regulation of gene expression by complementary pairing with specific mRNA sequences.

Trishula Therapeutics' Phase 1 trial of TTX-030 shows encouraging results for first-line treatment of metastatic pancreatic cancer.

the Danish pharmaceutical company Zealand Pharma announced clinical Phase 1 data for its long-acting amylin analogue, Petrelintide, which is being studied for weight management.